Board of Directors
Cipher’s board of directors has decades of experience and a proven record of success in all facets needed to efficiently develop and commercialize dermatology products.
Dedication to our vision is paramount to our success as we expand our product offerings and presence in North America.
Craig Mull is an accomplished executive previously involved in building CML Healthcare from $20 million annualized revenue to over $235 million and its public company launch to the capital markets. Additionally, Craig is CEO and founder of Typhon Group Ltd., a real estate development firm. He holds an Honours Business Administration (HBA) from Ivey Business School at the University of Western Ontario..
Harold Wolkin is an accomplished investment banker and financial analyst with over 30 years of experience. Mr. Wolkin joined BMO Nesbitt Burns as a senior research analyst in 1983. He went on to serve as managing director in the Diversified Industries Group of BMO Capital Markets until January 2008. Most recently, Mr. Wolkin served as Executive Vice-President and Head of Investment Banking for Dundee Capital Markets. Mr. Wolkin has served on a number of public company and not-for-profit boards and currently serves as a director of Baylin Technologies Inc., BYND Cannasoft Enterprises Inc., Ceres Global Ag Corp, Deal Pro Capital Corporation, and EnviroGold Global Limited. He was the past President of the CFA Society of Toronto and has been a member of the Chartered Financial Institute since 1980. He is a member of the Institute of Corporate Directors.
Douglas Deeth is a founding member and the managing partner of the law firm of Deeth Williams Wall LLP. He is the former President of the Intellectual Property Law section of the Canadian Bar Association, and the former President of the International Federation of Intellectual Property Attorneys (FICPI) and has over 40 years of experience working with the pharmaceutical industry. Throughout most of his career Mr. Deeth has been extensively involved in product acquisition and licensing agreements in the pharmaceutical field. He was directly involved in almost all of the product and technology acquisition and license agreements of Biovail Corporation from its inception in 1987 until 2008. Mr. Deeth has been recognized in several international reviews as one of Canada’s leading intellectual property lawyers. He was a director of Trimel Pharmaceuticals Inc. (now Acerus Pharmaceuticals Corporation), and Concordia International Corp. (now ADVANZ PHARMA Corp.) and is on the board of IM Biotechnologies Inc. (a privately held Canadian biotechnology company). Mr. Deeth was admitted to the Bar of Ontario in 1976. He has a B.A.Sc. in Chemical Engineering from the University of Waterloo and an LL.B. from the University of Toronto, and has taught, written and spoken extensively on intellectual property law.
Hubert Walinski is currently the Chief Scientific Officer of AIC Global Holdings since August 2021. Previously, Dr. Walinski held various positions at Astrazeneca, including the Head of Medical (Respiratory, Immunology, Vaccines, Medical Excellence and Medical Information), Medical Director Europe and Canada, Respiratory & Immunology, and Scientific Director (Respiratory, Immunology and Auto-Immune) at Astrazeneca Canada. Prior to his time at Astrazeneca, Dr. Walinski held various positions at Boehringer-Ingelheim Canada. Dr. Walinski has a Ph.D, Faculty of Graduate Studies, Department of Pathology and Laboratory Medicine from the University of British Columbia and a B.Sc. (Honours), Biology (minor Biochemistry) from McMaster University.